April 09, 2014
A Massachusetts federal court rejected a motion to dismiss a putative class action accusing AMAG Pharmaceuticals Inc. and its bank underwriters of misleading investors about the risks of iron deficiency treatment Feraheme, ruling Monday that the suit could continue in light of the First Circuit's reviving the case.
August 15, 2011
A Massachusetts federal judge on Thursday tossed a putative class action brought by AMAG Pharmaceuticals Inc. shareholders against the company and its underwriters for allegedly misleading investors about the risks associated with AMAG's injectable iron deficiency treatment Feraheme.